Abstract

Huperzia serrata is a traditional herb and endangered Chinese medicinal material, which has attracted much attention due to its production of Huperzine A (HupA). In vitro propagation of H. serrata is considered a new way to relieve the resource pressure of H. serrata. In this study, three different genotypic wild H. serrata were used for in vitro propagation. Then, the antioxidant activity and the content of HupA in the regenerated H. serrata were investigated. The results showed the survival rate of the explant was increased to 25.37% when using multiple sterilization processes. The best induction medium for H. serrata was the Schenk and Hildebrandt (SH) medium supplemented with 0.5 mg·L−1 Naphthalene acetic acid (NAA) and 0.1 mg·L−1 2,4-Dichlorophenoxyacetic acid (2,4-D), where the regeneration rate of the explant was to 57.04%. The best proliferation medium was the SH medium with NAA (1.0 mg·L−1), as the biomass of in vitro tissue increased 164.17 ± 0.41 times. High-performance liquid chromatography analysis showed that the in vitro culture of three genotypes could produce HupA and the content of HupA was 53.90–87.17 µg·g−1. The antioxidant experiment showed that the methanol extract of in vitro H. serrata had higher antioxidant activity than that of wild H. serrata. This study provides a reliable in vitro H. serrata culture protocol and laid an important foundation for the antioxidant capacity of the thallus and the content of HupA.

Highlights

  • The results showed that the survival rate of explants from different sterilization methods was significantly different (Figure 1)

  • The results showed that the DPPH and ABTS radical scavenging activity of the in vitro H. serrata methanol extract (IVE) was significantly greater than that of the wild H. serrata methanol extract (WHE)

  • Our results of this study found that the antioxidant activity of thallus was stronger than that of wild H. serrata, indicating that the advantages of micropropagation of thallus to produce antioxidant metabolites makes it available to fulfill the high pharmaceutical demands

Read more

Summary

Introduction

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Alzheimer’s disease (AD) is a common neurodegenerative disease in aged population and has become the third leading cause of death after cardiovascular disease and cancer [1]. According to the world Alzheimer’s report of 2018, there are about 50 million AD patients in the world, and it will increase to 150 million by 2050. There are no effective drugs that can prevent AD pathogenesis or slow down its progression. Among the different therapeutic strategies of AD, an increase in the acetylcholine level in the brain using acetylcholinesterase inhibitors (AChEI) is considered to be an effective treatment to alleviate some of the symptoms of the disease [2].

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call